Drug & intervention
elacestrant
RxCUI 2628469
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
29 shownA Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerNCT07766018 · 2026-08-18
RECRUITINGElacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast CancerNCT07563595 · 2026-06-19
RECRUITINGElacestrant in Advanced Triple Positive Breast CancerNCT07612215 · 2026-05-13
RECRUITINGMarker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCNCT07242352 · 2026-04-29
RECRUITINGPhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)NCT07222215 · 2026-01-16
RECRUITINGERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerNCT07198724 · 2025-11-17
RECRUITINGA Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerNCT07159451 · 2025-10-06
RECRUITINGCirculating Tumor DNANCT06923527 · 2025-09-30
RECRUITINGElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05
RECRUITINGA First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerNCT06638307 · 2024-10-25
RECRUITINGA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27
RECRUITINGDCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentNCT06075953 · 2024-02-17
RECRUITINGElacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15
RECRUITINGBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01
RECRUITINGElacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · 2023-02-03
RECRUITINGPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerNCT05573126 · 2023-01-11
RECRUITINGStudy of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerNCT05386108 · 2022-08-31
RECRUITINGMedical Imaging to Re-evaluate Elacestrant Clinical UsageNCT07753954 · 2026-09-13
NOT_YET_RECRUITINGHormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyNCT07005882 · 2025-09-01
NOT_YET_RECRUITINGImmunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast CancerNCT06691035 · 2024-11-04
ACTIVE_NOT_RECRUITINGSafety of Elacestrant in ER+/HER2- and ESR1 Mutations MBCNCT06544577 · 2024-07-13
UNKNOWNA Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerNCT06938711 · 2023-06-01
WITHDRAWNELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyNCT05596409 · 2023-05-19
ACTIVE_NOT_RECRUITINGOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerNCT05563220 · 2023-01-24
ACTIVE_NOT_RECRUITINGStudy of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerNCT05618613 · 2022-12-02
TERMINATEDPhase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerNCT04791384 · 2022-04-21
TERMINATEDElacestrant in Preoperative Setting, a Window of Opportunity StudyNCT04797728 · 2021-02-09
COMPLETEDPhase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT03778931 · 2019-05-10
COMPLETEDA Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerNCT02338349 · 2015-01-01
COMPLETEDConditions being studied
Breast Cancer14HER2-negative Breast Cancer6Metastatic Breast Cancer6Advanced Breast Cancer4ESR1 Gene Mutation3Breast Neoplasms2ER-positive Breast Cancer2Hormone Receptor Positive Breast Carcinoma2Hormone Receptor Positive HER-2 Negative Breast Cancer2HR+/HER2- Breast Cancer2Advanced ER+, HER2-Negative Breast Cancer1Advanced Solid Tumor1Brain Diseases1Brain Neoplasms1Breast Cancer Early Stage Breast Cancer (Stage 1-3)1Breast Cancer Female1Breast Cancer Metastatic Breast Cancer1Breast Cancer Patients1Breast Diseases1Central Nervous System Diseases1
Research locations
BarcelonaSpain9BostonMassachusetts, United States9MadridSpain9NashvilleTennessee, United States9ValenciaSpain8HoustonTexas, United States7San AntonioTexas, United States7ChicagoIllinois, United States6New YorkNew York, United States6TampaFlorida, United States6BaltimoreMaryland, United States5DallasTexas, United States5
Leading sponsors
Stemline Therapeutics, Inc.8Context Therapeutics Inc.2Kristina A. Fanucci2SOLTI Breast Cancer Research Group2Azienda Ospedaliero-Universitaria Careggi1BeOne Medicines1Criterium, Inc.1Ellipses Pharma1European Organisation for Research and Treatment of Cancer - EORTC1Gustave Roussy, Cancer Campus, Grand Paris1H. Lee Moffitt Cancer Center and Research Institute1iOMEDICO AG1Jules Bordet Institute1MedSIR1NYU Langone Health1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.